Antimicrob Agents Chemother. 2014 Mar 31. [Epub ahead of print]

Bumped Kinase Inhibitor 1294 Treats Established Toxoplasma gondii Infection

Doggett JS¹, Ojo KK, Fan E, Maly DJ, Van Voorhis WC.

Abstract

Toxoplasma gondii is a unicellular parasite that causes severe brain and eye disease. Current drugs for T. gondii are limited by toxicity. Bumped kinase inhibitors (BKI) selectively inhibit calcium-dependent protein kinases of the apicomplexan pathogens T. gondii, Cryptosporidia and Plasmodia. A lead anti-Toxoplasma BKI, 1294, has been developed to be metabolically stable and orally bioavailable. Herein, we demonstrate the oral efficacy of 1294 against toxoplasmosis in vivo.

PMID:

24687502

[PubMed - as supplied by publisher]